This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
Datroway — Description, Dosage, Side Effects | PillsCard
OTC
Datroway
INN: datopotamab deruxtecan
Data updated: 2026-05-14
Available in:
🇨🇿🇩🇪🇬🇧🇵🇹🇸🇰
Form
—
Dosage
—
Route
—
Storage
—
About This Product
Manufacturer
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Daiichi Sankyo Europe GmbH
ATC Code
L01FX35
Source
EMA · EMEA/H/C/006547
USDailyMed:can deruxtecan
L01FX35(WHO)
US:℞-onlyEU:Rx-only
2238831-60-0
DB16410
GD2OWY1DTK
D12359
Datopotamab deruxtecan, sold under the brand nameDatroway, is ananti-cancer medicationused for the treatment ofbreast cancer.It is aTrop-2-directed antibody andtopoisomeraseinhibitorantibody-drug conjugate.
The most common adverse reactions, including laboratory abnormalities, include stomatitis, nausea, fatigue, decreased leukocytes, decreased calcium, alopecia, decreased lymphocytes, decreased hemoglobin, constipation, decreased neutrophils, dry eye, vomiting, increased ALT, keratitis, increased AST, and increased alkaline phosphatase.
Datopotamab deruxtecan was approved for medical use in the United States in January 2025,and in the European Union in April 2025.